<DOC>
<DOCNO>EP-0635017</DOCNO> 
<TEXT>
<INVENTION-TITLE>
INDOLE DERIVATIVES AS 5-HT1 AGONISTS.
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3140	A61K3140	A61K31403	A61K31404	A61K3141	A61K3141	A61P300	A61P304	A61P900	A61P908	A61P912	A61P2500	A61P2504	A61P2506	A61P2520	A61P2524	A61P2526	A61P4300	A61P4300	C07D20700	C07D20708	C07D20900	C07D20904	C07D26300	C07D26308	C07D40300	C07D40306	C07D41300	C07D41312	C07D41314	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61K	A61K	A61K	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61P3	A61P3	A61P9	A61P9	A61P9	A61P25	A61P25	A61P25	A61P25	A61P25	A61P25	A61P43	A61P43	C07D207	C07D207	C07D209	C07D209	C07D263	C07D263	C07D403	C07D403	C07D413	C07D413	C07D413	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Compounds of formula (I) where W is (i), (ii), (iii), (iv), (v), (vi), or (vii); n is 0, 1 or 2; m is 0, 1, 2, or 3; Y and G are each independently oxygen or sulfur; Z is -O-, -S-, -NH-, or -CH2; R1 is hydrogen, C1 to C8 alkyl, substituted C1 to C8 alkyl substituted with one hydroxy, C3 to C8 alkenyl, C3 to C8 alkynyl, aryl, C1 to C3 alkylaryl, C1 to C3 alkylheteroaryl, or -Q-R4; R2 and R3 are each independently hydrogen, C1 to C6 alkyl, aryl, C1 to C3 alkylaryl, or C1 to C3 alkylheteroaryl; R4 is cyano, trifluoromethyl, -COR9, -CO2R9, -CONR9R10, -OR9, -SO2NR9R10, or -S(O)qR9; R9 and R10 are each independently hydrogen, C1 to C8 alkyl, C1 to C3 alkylaryl, aryl, or R9 and R10 may together be taken to form a three-to seven-membered alkyl ring or a three-to seven-membered heteroalkyl ring having 1 heteroatom of O; Q is C1 to C3 alkyl; R11 is hydrogen, -OR12, or -NHCOR12; R12 is hydrogen, C1 to C6 alkyl, aryl, or C1 to C3 alkylaryl; q is 0, 1, or 2; a first chiral carbon is designated by an asterisk; a second chiral carbon is designated by #; and the above aryl groups and the aryl moieties of the above alkyl-aryl groups are independently selected from phenyl and substituted phenyl, wherein said substituted phenyl may be substituted with one to three groups selected from C1 to C4 alkyl, halogen, hydroxy, cyano, carboxamido, nitro, and C1 to C4 alkoxy, and the pharmaceutically acceptable salts thereof. These compounds are useful in treating migraine and other disorders are new. These compounds are useful phsychotherapeutics and are potent serotonin (5-HT1) agonists and may be used in the treatment of depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain, and chronic paroxysmal hemicrania and headache associated with vascular disorders, and other disorders arising from deficient serotonergic neurotransmission. The compounds can also be used as centrally acting antihypertensives and vasodilators.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
PFIZER
</APPLICANT-NAME>
<APPLICANT-NAME>
PFIZER INC.
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
MACOR JOHN E
</INVENTOR-NAME>
<INVENTOR-NAME>
WYTHES MARTIN J
</INVENTOR-NAME>
<INVENTOR-NAME>
MACOR, JOHN, E.
</INVENTOR-NAME>
<INVENTOR-NAME>
WYTHES, MARTIN, J.
</INVENTOR-NAME>
</INVENTORS>
<DESCRIPTION>
 INDOLE DERIVATIVES AS 5-HT1 AGONISTSBackground of the Invention The present invention relates to indole derivatives, to processes and intermediates fortheir preparation, to pharmaceutical compositions containing them and to their medicinal use. The active compounds of the present invention are useful in treating migraine and other disorders.United States Patents 4,839,377 and 4,855,314 and European Patent Application Publication Number 313397 refer to 5-substituted 3-aminoalkyl indoles. The compounds are said to be useful for the treatment of migraine.British Patent Application 040279 refers to 3-aminoalkyl-1 H-indole-5-thioamides and carboxamides. The compounds are said to be useful in treating hypertension, Raymond's disease and migraine.European Patent Application Publication Number 303506 refers to 3-poly:hydro- pyridyl-5-substituted-1H-indoles. The compounds are said to have 5-HT, receptor agonist and vasoconstrictor activity and to be useful in treating migraine. European Patent Application Publication Number 354777 refers to N- piperidinyl:indolyl:ethyl-alkane sulfonamide derivatives. The compounds are said to have 5-HT1 receptor agonist and vasoconstrictor activity and to be useful in treating cephalic pain.European Patent Applications Publication Numbers 438230, 494774, and 497512 refers to indole-substituted five-membered heteroaromatic compounds. The compounds are said to have 5-HT^Iike receptor agonist activity and to be useful in the treatment of migraine and other disorders for which a selective agonist of these receptors is indicated.International Patent Application PCT/GB91/00908 and European Patent Application No. 313397A refers to 5-heterocyclic indole derivatives. The compounds are said to exhibit properties useful in the treatment and prophylaxis of migraine, cluster headache, and headache associated with vascular disorders. These compounds are also said to have "δ- TVIike" receptor agonism. •Summary of the Invention The present invention relates to compounds of the formula 

 U-where W is( i ) < i i ) < i i i > C i v )( v ) Cv i ) ( v i i )n is 0, 1, or 2; m is 0, 1, 2, or 3; Y and G are each independently oxygen or sulfur; Z is -O-, -S-, -NH, or -CH2; R, is hydrogen, C, to C8 alkyl, substituted C, to C8 alkyl substituted with one hydroxy, C3 to C8 alkenyl, C3 to C8 alkynyl, aryl, C, to C3 alkylaryl, C, to C3 alkylheteroaryl, or -Q-R4; R2 and R3 are each independently hydrogen, C, to Cβ alkyl, aryl, C, to C3 alkylaryl, or C, to C3 alkylheteroaryl; R4 is cyano, trifluoromethyl,
</DESCRIPTION>
<CLAIMS>
CLAIMS 1. A compound of the formula
where W is
<
 i ) 
<
 i i 
>
 ( i i i ) ( i v 
>
<
 v ) ( v i ) 
<
 v i i )
n is 0, 1 , or 2; m is 0, 1 , 2, or 3: Y and G are each independently oxygen or sulfur; Z is -O-, -S-, -NH, or -CH
2
; R, is hydrogen, C, to C
8
 alkyl, substituted C, to C
8
 alkyl substituted with one hydroxy, C
3
 to C
8
 alkenyl, C
3
 to C
8
 alkynyl, aryl, C, to C
3
 alkylaryl, C, to C
3
 alkylheteroaryl, or -Q-R
4
; R
2
 and R
3
 are each independently hydrogen, C, to C
β
 alkyl, aryl, C, to C
3
 alkylaryl, or C, to C
3
 alkylheteroaryl; R
4
 is cyano, trifluoromethyl, -COR
9
, -CO
2
R
9
, -CONR
9
R,
0
, -OR,, -SO
2
NR
9
R,
0
, or -S(O)
q
R
9
; R
9
 and R,
0
 are each independently hydrogen, C, to C
8
 alkyl, C, to C
3
 alkylaryl, aryl, or R
9
 and R
10
 may together be taken to form a three- to seven-membered alkyl ring or a three- to seven- membered heteroalkyl ring having 1 heteroatom of O; Q is C, to C
3
 alkyl; R,, is hydrogen, -OR
12
, or -NHCOR
12
; R
12
 is hydrogen, C, to C
β
 alkyl, aryl, or C, to C
3
 alkyl¬ aryl; q is 0, 1 , or 2; a first chiral carbon is designated by an asterisk; a second chiral 


carbon is designated by #; and the above aryl groups and the aryl moieties of the above alkyl-aryl groups are independently selected from phenyl and substituted phenyl, wherein said substituted phenyl may be substituted with one to three groups selected from C, to C
4
 alkyl, halogen, hydroxy, cyano, carboxamido, nitro, and C, to C
4
 alkoxy, and the pharmaceutically acceptable salts thereof.
2. The compound of claim 1 , wherein the compound of formula I is
3. The compound of claim 2, wherein the compound is the cjs epimer.
4. The compound of claim 1 , wherein the compound of formula I is the S epimer having the chiral carbon designated by #.
5. The compound of claim 1 , wherein G is oxygen.
6. The compound of claim 1, wherein W is (i), (ii), (iii), or (iv); R, is hydrogen, C, to C
β
 alkyl, aryl, C, to C
3
 alkylaryl, C, to C
3
 alkylheteroaryl, or -Q-R
4
; and R
4
 is cyano, trifluoromethyl, -CO
2
CH
3
, -CONH
2
, -OH, -OCH
3
, or -O-phenyl.
7. The compound of claim 6, wherein the compound of formula I is
8. The compound of claim 7, wherein the compound is the cjs epimer.
9. The compound of claim 6, wherein the compound of formula I is the S epimer having the chiral carbon designated by #. 


 10. The compound of claim 1 , wherein W is (i), (ii), or (iii); n is 1 ; m is 1 ; R, is hydrogen, C, to C
3
 alkyl, or -CH
2
CH
2
OCH
3
; R
2
 is hydrogen; and R
3
 is hydrogen or
-CH
2
Ph.
11. The compound of claim 10, wherein the compound of formula I is
12. The compound of claim 11 , wherein the compound is the cjs epimer.
13. The compound of claim 10, wherein the compound of formula I is the S epimer having the chiral carbon designated by #. 14. The compound of claim 1 , said compound being selected from
3-[(N-2-Methoxyethyl)pyrrolidin-2R-ylmethyl]-5-(2-oxo-1,3-oxazolidin-4S-ylmethyl)- 1 H-indole;
5-(2-Oxo-1 ,3-oxazolidin-4S-ylmethyl)-3-(pyrrolidin-2R-ylmethyl)-1 H-indole; and 3-(N-Methylpyrrolidin-2R-ylmethyl)-5-(2-oxo-1 ,3-oxazolidin-4R,S-ylmethyl)-1 H- indole.
15. A pharmaceutical composition for treating a condition selected from hypertension, depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain, and chronic paroxysmal hemicrania and headache associated with vascular disorders comprising an amount of a compound according to claim 1 effective in treating such condition and a pharmaceutically acceptable carrier.
16. A pharmaceutical composition for treating disorders arising from deficient serotonergic neurotransmission comprising an amount of a compound according to claim 1 effective in treating such a disorder and a pharmaceutically acceptable carrier. 17. A method for treating a condition selected from hypertension, depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain, and chronic paroxysmal hemicrania and headache associated with vascular 


disorders comprising administering to a mammal requiring such treatment an amount of a compound according to claim 1 effective in treating such condition.
18. A method for treating disorders arising from deficient serotonergic neurotransmission comprising administering to a mammal requiring such treatment an amount of a compound according to claim 1 effective in treating such condition.
19. A compound of the formula
where W is
( i ) (i i 
>
 Ci i i ) ( iv)
(v ) ( v i ) 
<
 v i i )
n is 0, 1 , or 2; m is 0, 1 , 2, or 3; Y and G are each independently oxygen or sulfur; Z is -O-, -S-, -NH, or -CH
2
; R
2
 and R
3
 are each independently hydrogen, C, to C
6
 alkyl, aryl, C, to C
3
 alkylaryl, or C, to C
3
 alkylheteroaryl; Rg is C, to C
β
 alkyl, aryl, or C, to C
3
 alkylaryl; R„ is hydrogen, -OR
12
, or -NHCOR
12
; R
12
 is hydrogen, C, to C
β
 alkyl, aryl, or C, to C
3
 alkyl-aryl; a first chiral carbon is designated by an asterisk; a second chiral carbon is designated by #; and the above aryl groups and the aryl moieties of the 


above alkyl-aryl groups are independently selected from phenyl and substituted phenyl, wherein said substituted phenyl may be substituted with one to three groups selected from C, to C
4
 alkyl, halogen, hydroxy, cyano, carboxamido, nitro, and C, to C
4
 alkoxy. 20. The compound of claim 19, wherein the compound of formula II is
21. The compound of claim 20, wherein the compound is the cjs epimer.
22. The compound of claim 19, wherein the compound of formula II is the S epimer having the chiral carbon designated by #.
23. The compound of claim 19, wherein G is oxygen.
24. A compound of the formula
U- (
where W is
( i ) ( i i ) ( i i i ) ( i v ) 

(
 v 
)
 Cv i ) ( v i i )
n is 0, 1 , or 2; m is 0, 1 , 2, or 3; Y and G are each independently oxygen or sulfur; Z is -O-, -S-, -NH, or -CH
2
; R
2
 and R
3
 are each independently hydrogen, C, to C„ alkyl, aryl, C, to C
3
 alkylaryl, or C, to C
3
 alkylheteroaryl; Rg is C, to C
β
 alkyl, aryl, or C, to C
3
 alkylaryl; Rg is halogen; R
7
 is -COCF
3
, -SO
2
CH
3
, -SO
2
Ph, or -CO
2
C(CH
3
)
3
; R„ is hydrogen, -OR
12
, or -NHCOR
12
; R
12
 is hydrogen, C
x
 to C
β
 alkyl, aryl, or C, to C
3
 alkyl¬ aryl; a first chiral carbon is designated by an asterisk; a second chiral carbon is designated by #; and the above aryl groups and the aryl moieties of the above alkyl- aryl groups are independently selected from phenyl and substituted phenyl, wherein said substituted phenyl may be substituted with one to three groups selected from C, to C
4
 alkyl, halogen, hydroxy, cyano, carboxamido, nitro, and C, to C
4
 alkoxy.
25. The compound of claim 24, wherein the compound of formula III is
26. The compound of claim 25, wherein the compound is the cjs epimer.
27. The compound of claim 24, wherein the compound of formula 111 is the S epimer having a chiral carbon designated by #. 28. The compound of claim 24, wherein G is oxygen.
29. A compound of the formula 

n is 0, 1 , or 2; R, is hydrogen, C, to C
8
 alkyl, substituted C, to C
8
 alkyl substituted with one hydroxy, C
3
 to C
8
 alkenyl, C
3
 to C
8
 alkynyl, aryl, C, to C
3
 alkylaryl, C, to C
3
 alkylheteroaryl, or -Q-R
4
; R
5
 is C, to C
β
 alkyl, aryl, or C, to C
3
 alkylaryl; R
4
 is cyano, trifluoromethyl, -COR
9
, -CO
2
R
9
, -CONR
9
R,
0
, -OR
9
, -SO
2
NR
9
R
10
, or -S(O)
q
R
9
; R
9
 and R,
0
 are each independently hydrogen, C, to C
8
 alkyl, C, to C
3
 alkylaryl, aryl, or R
9
 and R,
0
 may together be taken to form a three- to seven-membered alkyl ring or a three- to seven-membered heteroalkyl ring having 1 heteroatom of O; R,, is hydrogen, -OR,
2
, or- NHCOR
12
; R,
2
 is hydrogen, C, to C
β
 alkyl, aryl, or C, to C
3
 alkyl-aryl; R,
3
 is C, to C
6
 alkyl, aryl, or C, to C
3
 alkyl-aryl; q is 0, 1 , or 2; Q is C, to C
3
 alkyl; a first chiral carbon is designated by an asterisk; and the above aryl groups and the aryl moieties of the above alkyl-aryl groups are independently selected from phenyl and substituted phenyl, wherein said substituted phenyl may be substituted with one to three groups selected from C, to C
4
 alkyl, halogen, hydroxy, cyano, carboxamido, nitro, and C, to C
4
 alkoxy. 30. The compound of claim 29, wherein the compound of formula XIV is
31. The compound of claim 30, wherein the compound is the cjs epimer. 32. A compound of the formula 

n is 0, 1, or 2; J is -OH or -CO
2
R
13
; R, is hydrogen, C, to C
8
 alkyl, substituted C, to C
8
 alkyl substituted with one hydroxy, C
3
 to C
8
 alkenyl, C
3
 to C
8
 alkynyl, aryl, C, to C
3
 alkylaryl, C, to C
3
 alkylheteroaryl, or -Q-R
4
; R
4
 is cyano, trifluoromethyl, -COR
9
, -CO
2
R
9
, -CONR
9
R
10
, -OR
9
, -SO
2
NR
9
R
10
, or -S(O)
q
R
9
; R
9
 and R,
0
 are each independently hydrogen, C, to C
8
 alkyl, C, to C
3
 alkylaryl, aryl, or R
9
 and R
10
 may together be taken to form a three- to seven-membered alkyl ring or a three- to seven-membered heteroalkyl ring having 1 heteroatom of O; R is hydrogen, -OR
12
, or -NHCOR
12
; R
12
 is hydrogen, C, to C
β
 alkyl, aryl, or C, to C
3
 alkyl-aryl; R,
3
 is C, to C
β
 alkyl, aryl, or C, to C
3
 alkyl-aryl; q is 0, 1, or 2; Q is C, to C
3
 alkyl; a first chiral carbon is designated by an asterisk; a second chiral carbon is designated by #; and the above aryl groups and the aryl moieties of the above alkyl-aryl groups are independently selected from phenyl and substituted phenyl, wherein said substituted phenyl may be substituted with one to three groups selected from C, to C
4
 alkyl, halogen, hydroxy, cyano, carboxamido, n
'
rtro, and C, to C
4
 alkoxy.
33. The compound of claim 32, wherein the compound of formula XVII is
34. The compound of claim 33, wherein the compound is the cjs epimer.
35. The compound of claim 32, wherein the compound of formula XVII is the S epimer having a chiral carbon designated by #. 

</CLAIMS>
</TEXT>
</DOC>
